

# Francesca-Romana Spinelli

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8123753/francesca-romana-spinelli-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124 papers	2,064 citations	27 h-index	38 g-index
136 ext. papers	2,658 ext. citations	4.3 avg, IF	4.89 L-index

#	Paper	IF	Citations
124	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 58, 103-11	13.6	84
123	Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1393-7	2.4	78
122	Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. <i>Arthritis Research</i> , <b>2004</b> , 6, R366-72		68
121	HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. <i>Science Immunology</i> , <b>2020</b> , 5,	28	66
120	The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort. <i>Lupus</i> , <b>2016</b> , 25, 719-26	2.6	53
119	Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. <i>Journal of Immunology Research</i> , <b>2015</b> , 2015, 745647	4.5	53
118	Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. <i>PLoS ONE</i> , <b>2012</b> , 7, e33824	3.7	52
117	Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. <i>Annals of the Rheumatic Diseases</i> , <b>2002</b> , 61, 723-5	2.4	52
116	Autophagy and Rheumatoid Arthritis: Current Knowledges and Future Perspectives. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1577	8.4	51
115	Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1936	8.4	51
114	A multilocus genetic study in a cohort of Italian SLE patients confirms the association with STAT4 gene and describes a new association with HCP5 gene. <i>PLoS ONE</i> , <b>2014</b> , 9, e111991	3.7	47
113	TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. <i>Immunogenetics</i> , <b>2013</b> , 65, 703-9	3.2	44
112	Ultrasound evaluation of hand, wrist and foot joint synovitis in systemic lupus erythematosus. <i>Rheumatology</i> , <b>2014</b> , 53, 465-72	3.9	43
111	Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on $\alpha$ GPI-specific T cell response. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2014</b> , 34, 661-8	9.4	42
110	Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. <i>PLoS ONE</i> , <b>2012</b> , 7, e45934	3.7	41
109	Assessment of disease activity in Systemic Lupus Erythematosus: Lights and shadows. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 601-8	13.6	40
108	Effect of therapeutic inhibition of TNF on circulating endothelial progenitor cells in patients with rheumatoid arthritis. <i>Mediators of Inflammation</i> , <b>2013</b> , 2013, 537539	4.3	39

107	To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 666-667	2.4	37
106	Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 276	5.7	35
105	Fatigue and widespread pain in systemic lupus erythematosus and Sjögren's syndrome: symptoms of the inflammatory disease or associated fibromyalgia?. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 117-21	2.2	35
104	Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 47, 53-64	5.3	34
103	Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. <i>Mediators of Inflammation</i> , <b>2012</b> , 2012, 347268	4.3	33
102	The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , <b>2015</b> , 2015, 712490	4.5	31
101	Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 214	2.8	28
100	The role of dietary sodium intake on the modulation of T helper 17 cells and regulatory T cells in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184449	3.7	28
99	Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 126	5.7	27
98	Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. <i>Lupus</i> , <b>2014</b> , 23, 743-51	2.6	27
97	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 164-176	13.6	27
96	Low expression of estrogen receptor $\alpha$ in T lymphocytes and high serum levels of anti-estrogen receptor $\alpha$ antibodies impact disease activity in female patients with systemic lupus erythematosus. <i>Biology of Sex Differences</i> , <b>2016</b> , 7, 3	9.3	26
95	Reduction of autophagy and increase in apoptosis correlates with a favorable clinical outcome in patients with rheumatoid arthritis treated with anti-TNF drugs. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 39	5.7	25
94	Serial interferon- $\gamma$ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 1567-75	3.9	25
93	SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 953-954	2.4	24
92	Biological therapies in rheumatic diseases. <i>Clinica Terapeutica</i> , <b>2013</b> , 164, e413-28	1	22
91	Prediction of chronic damage in systemic lupus erythematosus by using machine-learning models. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174200	3.7	21
90	Association between Staphylococcus aureus nasal carriage and disease phenotype in patients affected by systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 177	5.7	21

89	Kidney Expression of Toll Like Receptors in Lupus Nephritis: Quantification and Clinicopathological Correlations. <i>Mediators of Inflammation</i> , <b>2016</b> , 2016, 7697592	4.3	21
88	Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207926	3.7	21
87	Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. <i>Mediators of Inflammation</i> , <b>2015</b> , 2015, 328078	4.3	20
86	Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 954-63	2.2	20
85	Asymmetric Dimethyl Arginine as a Biomarker of Atherosclerosis in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , <b>2018</b> , 2018, 3897295	4.3	19
84	Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. <i>Drug Development Research</i> , <b>2014</b> , 75 Suppl 1, S67-9	5.1	17
83	Pain and systemic lupus erythematosus. <i>Reumatismo</i> , <b>2014</b> , 66, 33-8	1.1	17
82	Toll-like receptors and lupus nephritis. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2011</b> , 40, 192-8	12.3	17
81	Post-translational modifications in rheumatoid arthritis and atherosclerosis: Focus on citrullination and carbamylation. <i>Journal of International Medical Research</i> , <b>2016</b> , 44, 81-84	1.4	17
80	Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. <i>Lupus</i> , <b>2000</b> , 9, 676-80	2.6	16
79	Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. <i>Lupus</i> , <b>2018</b> , 27, 105-111	2.6	15
78	Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. <i>Immunologic Research</i> , <b>2014</b> , 60, 270-6	4.3	15
77	Autoantibody production in anti-TNF-alpha-treated patients. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 319-29	6.5	15
76	Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab. <i>Cytokine</i> , <b>2017</b> , 96, 16-23	4	14
75	Cognitive dysfunction improves in systemic lupus erythematosus: Results of a 10 years prospective study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196103	3.7	14
74	Emergence of antinuclear antibodies in psoriatic patients treated with infliximab: personal experience and literature review. <i>Drug Development Research</i> , <b>2014</b> , 75 Suppl 1, S61-3	5.1	14
73	TLC immunostaining for detection of "antiphospholipid" antibodies. <i>Methods in Molecular Biology</i> , <b>2014</b> , 1134, 95-101	1.4	14
72	Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. <i>Immunologic Research</i> , <b>2017</b> , 65, 524-531	4.3	13

71	Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , <b>2020</b> , 10, 5851	4.9	13
70	The role of disease activity score 28 in the evaluation of articular involvement in systemic lupus erythematosus. <i>Scientific World Journal, The</i> , <b>2014</b> , 2014, 236842	2.2	13
69	JAK inhibitors: Ten years after. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 1615-1627	6.1	13
68	Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. <i>Lupus</i> , <b>2018</b> , 27, 1616-1623	2.6	12
67	Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset. <i>Lupus</i> , <b>2015</b> , 24, 1276-82	2.6	12
66	Evaluation of the patient acceptable symptom state (PASS) in Italian patients affected by systemic lupus erythematosus: association with disease activity indices. <i>PLoS ONE</i> , <b>2013</b> , 8, e73517	3.7	12
65	Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1555-6; author reply 1556-7		12
64	Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 460	8.4	11
63	Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. <i>Rheumatology</i> , <b>2011</b> , 50, 1148-52	3.9	11
62	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. <i>Rheumatology</i> , <b>2020</b> , 59, 2272-2281	3.9	11
61	B lymphocyte stimulator modulates number and function of endothelial progenitor cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 245	5.7	11
60	TNF $\alpha$ expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 273	5.7	11
59	Early Lupus Project: one-year follow-up of an Italian cohort of patients with systemic lupus erythematosus of recent onset. <i>Lupus</i> , <b>2018</b> , 27, 1479-1488	2.6	10
58	Jaccoud's arthropathy in systemic lupus erythematosus: clinical, laboratory and ultrasonographic features. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 674-677	2.2	10
57	A Monocentric Cohort of Obstetric Seronegative Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1678	8.4	9
56	Ultrasonographic evaluation of renal resistive index in patients with lupus nephritis: correlation with histologic findings. <i>Ultrasound in Medicine and Biology</i> , <b>2014</b> , 40, 2573-80	3.5	9
55	Biological drug treatment of rheumatoid arthritis and spondyloarthritis: effects on QT interval and QT dispersion. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 41-5	4.1	9
54	Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 606-608	0.7	8

53	Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 3145-3151	3.9	8
52	Acute longitudinal myelitis following <i>Cryptococcus laurentii</i> pneumonia in a patient with systemic lupus erythematosus. <i>Lupus</i> , <b>2015</b> , 24, 94-7	2.6	8
51	Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials. <i>Archivos De Bronconeumologia</i> , <b>2020</b> , 56, 606-608	0.7	8
50	Homocysteinylation of alpha 1 antitrypsin as an antigenic target of autoantibodies in seronegative rheumatoid arthritis patients. <i>Journal of Autoimmunity</i> , <b>2020</b> , 113, 102470	15.5	7
49	Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio. <i>Reumatismo</i> , <b>2015</b> , 67, 62-7	1.1	7
48	Ultrasonographic Evaluation of Resistive Index and Renal Artery Stenosis in Patients with Anti-Phospholipid Syndrome: Two Distinct Mechanisms?. <i>Ultrasound in Medicine and Biology</i> , <b>2015</b> , 41, 1814-20	3.5	6
47	Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	6
46	Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 21	5.7	6
45	Reactive arthritis: current treatment challenges and future perspectives. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1065-1076	2.2	6
44	CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients. <i>Lupus</i> , <b>2019</b> , 28, 621-628	2.6	5
43	Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy. <i>Clinical Immunology</i> , <b>2018</b> , 195, 18-27	9	5
42	Early response to apremilast treatment in psoriatic arthritis: a real-life ultrasonographic follow-up study. <i>Rheumatology</i> , <b>2018</b> , 57, 1490-1491	3.9	5
41	Induction of remission in rheumatoid arthritis: criteria and opportunities. <i>Rheumatology International</i> , <b>2008</b> , 29, 131-9	3.6	5
40	Microparticles and autophagy: a new frontier in the understanding of atherosclerosis in rheumatoid arthritis. <i>Immunologic Research</i> , <b>2018</b> , 66, 655-662	4.3	5
39	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
38	Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score. <i>Lupus</i> , <b>2019</b> , 28, 383-388	2.6	3
37	Low incidence of flare and persistent active disease in a cohort of Italian patients with systemic lupus erythematosus: comment on the article by Nikpour et al. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 899-900; author reply 900	4.7	3
36	JAK1: Number one in the family; number one in inflammation?. <i>Rheumatology</i> , <b>2021</b> , 60, ii3-ii10	3.9	3

35	ISG15 protects human Tregs from interferon alpha-induced contraction in a cell-intrinsic fashion. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1221	6.8	3
34	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 19-26 <sup>2,2</sup>	2.2	3
33	Janus kinases inhibitors for treating patients with rhupus. <i>Joint Bone Spine</i> , <b>2020</b> , 87, 673-674	2.9	2
32	Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study. <i>Clinical Rheumatology</i> , <b>2018</b> , 37, 2573-2577	3.9	2
31	Pragmatic language dysfunction in systemic lupus erythematosus patients: Results from a single center Italian study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224437	3.7	2
30	Monitoring biological therapies in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2009</b> , 83, 69-70		2
29	Joint involvement influences quality of life in systemic lupus erythematosus patients. <i>Lupus</i> , <b>2021</b> , 30, 478-483	2.6	2
28	Caffeine intake influences disease activity and clinical phenotype in systemic lupus erythematosus patients. <i>Lupus</i> , <b>2020</b> , 29, 1377-1384	2.6	2
27	"Non-criteria antiphospholipid antibodies": bridging the gap between seropositive and seronegative Antiphospholipid Syndrome. <i>Rheumatology</i> , <b>2021</b> ,	3.9	2
26	Response to Q& there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Qby Moiseev. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e20	2.4	2
25	Reprint of "Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab". <i>Cytokine</i> , <b>2018</b> , 101, 70-77	4	2
24	The role of osteopontin as a candidate biomarker of renal involvement in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 899-905	2.2	2
23	Effectiveness and safety of baricitinib in rheumatoid arthritis: a monocentric, longitudinal, real-life experience. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 525-531	2.2	2
22	Anti-D4GDI antibodies activate platelets in vitro: a possible link with thrombocytopenia in primary antiphospholipid syndrome. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 161	5.7	1
21	Developing new evaluation methods in systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , <b>2015</b> , 10, 479-488	1.5	1
20	Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
19	Management of mycophenolate mofetil-induced acne in patients with Systemic Lupus Erythematosus: report of four cases and review of the literature. <i>Mediterranean Journal of Rheumatology</i> , <b>2018</b> , 29, 217-220	1.4	1
18	Erosive arthritis in systemic lupus erythematosus: not only Rhupus. <i>Lupus</i> , <b>2021</b> , 30, 2029-2041	2.6	1

17	Can machine learning models support physicians in systemic lupus erythematosus diagnosis? Results from a monocentric cohort. <i>Joint Bone Spine</i> , <b>2021</b> , 89, 105292	2.9	1
16	Response to Q To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic Q by Parperis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e9	2.4	1
15	An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica. <i>Scientific Reports</i> , <b>2020</b> , 10, 11407	4.9	1
14	Correspondence to Q Gender gap in rheumatology: speaker representation at annual conferences Q by Monga and Liew-gender discrepancies at annual EULAR congresses: towards the gap narrowing. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
13	Correspondence on Q Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry Q by Gianfrancesco M. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
12	Comprehensive disease control in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 404-408	5.3	1
11	Genetic diversity of Staphylococcus aureus influences disease phenotype of systemic lupus erythematosus. <i>Rheumatology</i> , <b>2021</b> , 60, 958-966	3.9	1
10	Breastfeeding in women affected by systemic lupus erythematosus: Rate, duration and associated factors. <i>Lupus</i> , <b>2021</b> , 30, 913-920	2.6	1
9	Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: Comparison between renal and non-renal involvement. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105246	2.9	1
8	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , <b>2021</b> , 30, 1233-1243	2.6	0
7	Response to: Q Correspondence on Q SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists Q by Smerilli. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, e169	2.4	0
6	Pregnancy outcome in systemic lupus erythematosus patients: a monocentric cohort analysis. <i>Rheumatology</i> , <b>2021</b> , 60, 1747-1754	3.9	0
5	Application of Ultrasound in the Assessment of Oligoarticular Psoriatic Arthritis Subset: Results from Patients Treated with Apremilast. <i>Israel Medical Association Journal</i> , <b>2021</b> , 23, 412-415	0.9	0
4	Foreword: Seminars in Research 2014 Joint Experiences in Rheumatology and Dermatology. <i>Journal of International Medical Research</i> , <b>2016</b> , 44, 3-5	1.4	
3	Comment on: Temporal relationships between systemic lupus erythematosus and comorbidities. <i>Rheumatology</i> , <b>2019</b> , 58, 1698	3.9	
2	Comment on: Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , <b>2021</b> , 60, e334-e336	3.9	
1	Treatment with Gonadotropin Releasing Hormone Agonists in Systemic Lupus Erythematosus Patients Receiving Cyclophosphamide: A Long-term Follow-up Study. <i>Israel Medical Association Journal</i> , <b>2020</b> , 22, 343-347	0.9	